India-based bioinformatics firm Strand Life Sciences has introduced a new line of liquid biopsy tests STRAND LB to detect traces of cancer from a blood sample.

The highly sensitive test is designed for early and accurate identification of the presence of a tumour, recurrence of the disease and response to therapy.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The test claims to enable early evaluation with low patient discomfort, contrary to the invasive tumour biopsies and radioactive scans.

Strand Life Sciences chairman and managing director Dr Vijay Chandru said: "Liquid biopsy is a paradigm shift that involves a minimally invasive procedure, no radioactive scans, and can detect tumour DNA traces from a simple blood draw.

"However, detecting tumour DNA requires a highly sensitive test capable of detecting one molecule in 1,000.

"Our study on patients spanning a wide variety of cancer types, including lung, colorectal, breast, and bladder cancer, shows that STRAND LB can detect tumour DNA traces in as many as 35% of patients with early stage cancer, going up to 70-90% in patients with locally advanced or metastatic cancer."

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.
"STRAND LB can detect tumour DNA traces in as many as 35% of patients with early-stage cancer, going up to 70-90% in patients with locally advanced or metastatic cancer."

The STRAND LB tests were developed in collaboration with Mazumdar Shaw Center for Translational Research (MSCTR) and were validated by the Mazumdar Shaw Medical Center (MSMC).

The sensitivity of the test in detecting mutations is expected to allow for the early identification of cancer and treatment with personalised treatment plans.

It is estimated that the test can be used for approximately 30% of lung cancer patients whose biopsy material is not sufficient for the detection of tumour mutations.

The test can also discover traces of the tumour that cannot be detected by the naked eye or imaging scans in cancers such as breast and colorectal.